Illumina, Inc. (NASDAQ:ILMN), a leading company in the genomics field, has recently made several strides forward. Analysts have given the company an average recommendation of
'Hold'. The company's stock has a potential upside of 63% and its RS rating has jumped to 82. Illumina has formed a multiomic alliance with Regeneron, leading to an expansion in its investment story. It has been pushing for preventive genomics through DNA screening health plans. Furthermore, Illumina's whole-genome sequencing technology will accelerate rare disease testing in Florida.
JPMorgan Chase & Co. has acquired over 124,000 shares of Illumina. The company has launched TruPath Genome, setting a new standard in genomic insight. Moreover, it has seen a share price jump of 14.3% after expanding its rare-disease sequencing. Recent financial results for the fourth quarter and fiscal year 2025 have been positive. The company has initiated a partnership to drive cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics. Finally, Illumina has unveiled a roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility.
Illumina ILMN News Analytics from Thu, 24 Jul 2025 07:00:00 GMT to Sat, 21 Mar 2026 06:29:37 GMT -
Rating 8
- Innovation 7
- Information 8
- Rumor 5
